Gail Schulze
Director/Board Member bei CERUS CORPORATION
Vermögen: 233 264 $ am 31.03.2024
Profil
Gail Gaumer Schulze currently works at Cerus Corp., as Independent Director from 2007.
Ms. Schulze also formerly worked at Eximias Pharmaceutical Corp., as President, Chief Executive Officer & Director, Aventis Behring, as COO & Deputy Chief Executive Officer from 1997 to 2004, YM Biosciences USA, Inc., as Chief Executive Officer & Director from 2006 to 2007, ZP Opco, Inc., as Chairman in 2012, Baxter Healthcare Corp., as President-Renal Division Europe from 1979 to 1995, YM BioSciences, Inc., as President from 2006 to 2007, and Allegiance Healthcare Corp., as Vice President from 1996 to 1997.
Ms. Schulze received her undergraduate degree from the University of California, Santa Cruz and Masters Business Admin degree from Stanford Graduate School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CERUS CORPORATION
0,07% | 07.06.2023 | 123 420 ( 0,07% ) | 233 264 $ | 31.03.2024 |
Aktive Positionen von Gail Schulze
| Unternehmen | Position | Beginn |
|---|---|---|
| CERUS CORPORATION | Director/Board Member | 25.10.2007 |
Ehemalige bekannte Positionen von Gail Schulze
| Unternehmen | Position | Ende |
|---|---|---|
ZP Opco, Inc.
 ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Chairman | 01.06.2012 |
YM Biosciences USA, Inc.
 YM Biosciences USA, Inc. Pharmaceuticals: MajorHealth Technology YM Biosciences USA, Inc. develops and commercializes pharmaceutical products. The company was founded on November 23, 2005 and is headquartered in Wayne, PA. | Chief Executive Officer | 01.03.2007 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | President | 01.03.2007 |
| Aventis Behring | Chief Operating Officer | 01.01.2004 |
Allegiance Healthcare Corp.
 Allegiance Healthcare Corp. Medical DistributorsDistribution Services Allegiance Healthcare Corp. manufactures and distributes pharmaceutical products. It offers medical, surgical, and laboratory products. The company provides services to hospitals, laboratories, and others in the health care industries. The company was founded in 1999 and is headquartered in Waukegan, IL. | Corporate Officer/Principal | 01.01.1997 |
Ausbildung von Gail Schulze
| University of California, Santa Cruz | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CERUS CORPORATION | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Eximias Pharmaceutical Corp.
 Eximias Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Eximias Pharmaceutical Corp. develops pharmaceuticals for treatment of cancer disorders. It offers its services in the mid-Atlantic areas. The company is headquartered in Berwyn, PA. | Health Technology |
ZP Opco, Inc.
ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Health Technology |
Allegiance Healthcare Corp.
Allegiance Healthcare Corp. Medical DistributorsDistribution Services Allegiance Healthcare Corp. manufactures and distributes pharmaceutical products. It offers medical, surgical, and laboratory products. The company provides services to hospitals, laboratories, and others in the health care industries. The company was founded in 1999 and is headquartered in Waukegan, IL. | Distribution Services |
| Aventis Behring | Health Technology |
YM Biosciences USA, Inc.
YM Biosciences USA, Inc. Pharmaceuticals: MajorHealth Technology YM Biosciences USA, Inc. develops and commercializes pharmaceutical products. The company was founded on November 23, 2005 and is headquartered in Wayne, PA. | Health Technology |
